Sigurdsson Steinthor, Geirsson Gudmundur, Gudmundsdottir Hrefna, Egilsdottir Perla B, Gudbjarnason Sigmundur
SagaMedica, Reykjavik, Iceland.
Scand J Urol. 2013 Feb;47(1):26-32. doi: 10.3109/00365599.2012.695390. Epub 2012 Jul 2.
This study aimed to investigate the effect of SagaPro, a product derived from Angelica archangelica leaf, on nocturia.
Sixty-nine male patients 45 years or older with at least two nocturnal voids were randomized to receive SagaPro or placebo in a double-blind design for 8 weeks. Voiding diaries were assessed before and after the treatment.
The results indicate that SagaPro is safe. The actual number of nocturnal voids (ANV), nocturnal polyuria index (NPi) and nocturnal bladder capacity index (NBC index) decreased in the test population, but there was no significant difference between the treatment groups. Subsequent subgroup analysis showed that SagaPro significantly reduced the NBC index and nocturnal voids per sleeping hour in comparison to the placebo in participants with baseline NBC index above 1.3. When participants with sleep disorders were excluded from this group, ANV was also significantly reduced for the SagaPro group in comparison to the placebo group.
SagaPro, made from an extract of the medicinal herb Angelica archangelica, is safe. This study did not show that SagaPro improved nocturia overall compared to placebo. Subgroup analysis suggested a beneficial effect in individuals with decreased nocturnal bladder capacity, which warrants further study.
本研究旨在调查源自当归叶的产品SagaPro对夜尿症的影响。
69名45岁及以上、每晚至少有两次夜尿的男性患者被随机分配,以双盲设计接受SagaPro或安慰剂治疗,为期8周。在治疗前后评估排尿日记。
结果表明SagaPro是安全的。试验人群的实际夜尿量(ANV)、夜间多尿指数(NPi)和夜间膀胱容量指数(NBC指数)均有所下降,但治疗组之间无显著差异。随后的亚组分析显示,与基线NBC指数高于1.3的参与者中的安慰剂相比,SagaPro显著降低了NBC指数和每睡眠时间的夜尿量。当该组中排除睡眠障碍参与者时,与安慰剂组相比,SagaPro组的ANV也显著降低。
由药用植物当归提取物制成的SagaPro是安全的。本研究未表明SagaPro与安慰剂相比总体上改善了夜尿症。亚组分析表明对夜间膀胱容量降低的个体有有益作用,这值得进一步研究。